Pfizer and Moderna both Reported their COVID-19 Vaccines are About 95% Effective, However the Astrazeneca Vaccine Costs Less to Make
DUBLIN, Dec. 1, 2020 /PRNewswire/ -- ResearchAndMarkets.com published a new article on the COVID-19 Vaccine industry "Pfizer and Moderna both Reported their COVID-19 Vaccines are About 95% Effective"
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
AstraZeneca could conduct another global clinical trial to test the efficacy of its vaccine at a lower dosage. Interim results showed a 62% efficacy rate for the full two dose regimen and a 90% efficacy rate in a subgroup of trial participants who by error initially received a half dose followed by a full dose. AstraZeneca reported that the administering of the half dose had been reviewed by independent safety monitors and the British medicine regulator. Any further insights from the new trial will be added to those from existing trials that are being prepared for regulatory submission.
The new trial is not expected to delay British and European regulatory approvals. However, it could extend the length of time it takes for the vaccine to be approved in the US. The company intends to work with the US Food and Drug Administration to change the design of its late stage US trial to test the more effective half dose regimen. The vaccine is one of three that could be approved before the end of the year. This month Pfizer and Moderna both reported their vaccines were about 95% effective. However, the AstraZeneca vaccine costs less to make and can be transported and stored at refrigerated temperatures rather than frozen making it a valuable candidate for global vaccination programs.
To see the full article and a list of related reports on the market, visit "Pfizer and Moderna both Reported their COVID-19 Vaccines are About 95% Effective"
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/pfizer-and-moderna-both-reported-their-covid-19-vaccines-are-about-95-effective-however-the-astrazeneca-vaccine-costs-less-to-make-301182752.html
SOURCE Research and Markets
